Aktis Oncology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Aktis Oncology Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- AKTS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002035832
Board of directors
-
Glenn Gormley · DirectorSince 2026
-
Helen Susan Kim · DirectorSince 2026
-
Ken Herrmann · DirectorSince 2026
-
Lloyd Mitchell Segal · DirectorSince 2026
- Since 2026
-
Matthew Roden · Director · President and CEOSince 2026
-
Michael A. Sherman · DirectorSince 2026
-
Oleg Nodelman · DirectorSince 2026
-
Todd Foley · DirectorSince 2026
Chief executives
Matthew Roden
· President and CEO
Since January 2026
Board connections
4 of this board's directors also sit on 9 other boards.
- via Mary Thistle
- via Oleg Nodelman
- via Mary Thistle
- via Mary Thistle
- via Oleg Nodelman
- via Helen Susan Kim
- via Mary Thistle
- via Michael A. Sherman
- via Oleg Nodelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $114,311,628
- 9 purchases by 6 insiders
- Sold, last 12 months
- $3,231,412
- 11 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Czibere Akos Officer (Chief Medical Officer) | Option exercise | +12,500 | $4.95 | $61,875 |
| Sep 23, 2026 | Czibere Akos Officer (Chief Medical Officer) | Open-market sale | −5,099 | $20.19 | $102,973 |
| Sep 23, 2026 | Czibere Akos Officer (Chief Medical Officer) | Open-market sale | −7,401 | $21.03 | $155,648 |
| Jul 20, 2026 | Ken Herrmann Director | Option exercise | +3,506 | $0.08 | $280 |
| Jul 20, 2026 | Ken Herrmann Director | Option exercise | +1,350 | $1.91 | $2,579 |
| Jul 20, 2026 | Ken Herrmann Director | Open-market sale | −3,506 | $24.56 | $86,115 |
| Jul 20, 2026 | Ken Herrmann Director | Open-market sale | −1,350 | $24.56 | $33,159 |
| Jul 17, 2026 | Ken Herrmann Director | Option exercise | +3,065 | $0.08 | $245 |
| Jul 17, 2026 | Ken Herrmann Director | Open-market sale | −3,065 | $25.21 | $77,259 |
| Jul 8, 2026 | Czibere Akos Officer (Chief Medical Officer) | Option exercise | +50,000 | $4.95 | $247,500 |
| Jul 8, 2026 | Ron-Bigger Shulamit Officer (Chief Operating Officer) | Option exercise | +50,000 | $3.66 | $183,000 |
| Jul 8, 2026 | Czibere Akos Officer (Chief Medical Officer) | Open-market sale | −14,800 | $27.13 | $401,484 |
| Jul 8, 2026 | Ron-Bigger Shulamit Officer (Chief Operating Officer) | Open-market sale | −15,800 | $27.13 | $428,681 |
| Jul 8, 2026 | Czibere Akos Officer (Chief Medical Officer) | Open-market sale | −30,829 | $27.95 | $861,735 |
| Jul 8, 2026 | Ron-Bigger Shulamit Officer (Chief Operating Officer) | Open-market sale | −30,000 | $27.94 | $838,137 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.